All About

QuantumLeap Healthcare Collaborative

Established in 2005, QuantumLeap’s mission is to accelerate transfer of high-impact research in clinical processes and systems technology into widespread adoption so that patients and physicians can benefit from the research as soon as practicable.

I-SPY 2 Clinical Trial Results Announced at AACR 2016

April 18, 2016

San Francisco, CA—April 18, 2016 — QuantumLeap Healthcare Collaborative announced Results from the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) indicating that a neoadjuvant (presurgery) therapy combination of the antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) and pertuzumab (Perjeta) was more beneficial than paclitaxel plus trastuzumab for women with HER2-positive invasive breast cancer. Research was presented today at the AACR Annual Meeting 2016, April 16-20.

Read More
Check Out Our


QuantumLeap Healthcare Collaborative is currently engaged in four large projects with significant potential to improve quality, lower cost and personalize care for breast cancer patients and other cancer patients as well.


accelerating research into practice